Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. - Wikidata - awgldk - TriplyDB

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q37496608

about

Atherosclerosis and infection: is the jury still not in?A genome-wide association study of carotid atherosclerosis in HIV-infected men START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis Role of high-sensitivity C-reactive protein measurements in HIV patients Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa Inflammation, coagulation and cardiovascular disease in HIV-infected individuals HIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formation The burden of image based emphysema and bronchiolitis in HIV-infected individuals on antiretroviral therapy Preparedness of HIV care and treatment clinics for the management of concomitant non-communicable diseases: a cross-sectional survey.Accelerated atherosclerosis in a human immunodeficiency virus infected patient not on highly active anti-retroviral therapy: An autopsy case report.Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.Microbial translocation and cardiometabolic risk factors in HIV infection.Cardiovascular health of HIV-infected African-American women at the Miriam Hospital Immunology Center in Providence, RI Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis.Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.HIV-associated lipodystrophy: a review from a Brazilian perspective Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.HIV infection, inflammation, immunosenescence, and aging.Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis A history of alcohol dependence augments HIV-associated neurocognitive deficits in persons aged 60 and older.Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis Markers of atherosclerosis and inflammation and mortality in patients with HIV infection.Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need?Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China.Comparison of Serum Lipid Profile in HIV Positive Patients on ART with ART Naïve Patients.Immunologic basis of cardiovascular disease in HIV-infected adults.Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.Cardiovascular implications from untreated human immunodeficiency virus infection.The macrophage: the intersection between HIV infection and atherosclerosis.Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.A systematic review of the effects of different types of therapeutic exercise on physiologic and functional measurements in patients with HIV/AIDS.

P2860

Q22241306-454DFC6D-E642-44AA-B4FC-B3B9B49CFA9C Q24622468-0EB1E701-F6DB-4347-B057-89D75E5B2423 Q26753830-32F9607D-C033-40F2-91B4-C2B17892A0A8 Q26851535-02D90CAE-0A1B-4FAD-99F3-F877B454FEB1 Q27004131-786551A1-38F7-4D11-AF32-F58BCF89D5D0 Q28067891-B1BFAC4A-CEB7-4591-8626-C7D69A49386D Q28080289-2651E5BA-C31C-4C77-99E4-A3D5C83C1D52 Q28080948-D3A587FA-D6A4-4503-BFA3-F4C453432C77 Q28365108-7E71515A-EABA-4BF8-A6E8-6A099CA23587 Q28483645-482F5511-5AAE-4CB2-9CC4-DF2573D1C8C4 Q28541572-ECDE321E-8FD9-46AB-83D5-E71551D62135 Q28544453-8DCBCA3F-CE9C-44A9-87C4-D343BD3A0DF3 Q30151768-71EB5A9C-487A-40A2-BA61-C1E5AB4D57AA Q30410181-02E93A27-5E40-447B-9993-CB7A293CA1D0 Q31152445-99E88D27-82C6-4F6B-A5F6-C4D052AA3494 Q33603728-BD4D8645-D293-4A23-96FE-5AA34D9DE53C Q33713895-4E9029C5-050A-45FB-B463-133677F8C449 Q33737823-D89906A1-0358-40CF-9034-7F09FA949FF2 Q33828245-0086DEAB-B971-483E-A008-C252C008585E Q33828349-20A36939-A6B5-4534-9455-BB97B0233E12 Q33889580-A03F4ABD-0996-4C29-8F7B-775EF80E8E65 Q33939681-646D5CBF-1975-4559-A6DB-8B1D42BA2080 Q33944936-82D5F8E9-F6EE-4458-8348-3605F6C87006 Q34032348-2E304E75-316B-4F72-B102-2125F2402110 Q34150710-A8E30EDA-DC3C-4433-B2C0-FC3AA4875E12 Q34217096-21BE62D3-4563-4B66-B333-13B5878C60F3 Q34388983-0D428B3B-9839-4BC9-B5BA-840F0254E627 Q34423991-30B631A8-6A1A-46B8-A879-8EF08CDAA546 Q34430776-E1AD6485-B624-490E-BA1C-BE577A55CB87 Q34554934-0434E873-7D53-43C1-B10D-DF98F572785C Q34574778-D47FD956-77DE-4791-8EC5-918C40F0566C Q34581209-924BDF13-0A2E-458A-B544-07B1F89E6F8D Q34617937-5C68AEA8-F3AA-47B1-AEEC-7DC2502FFC96 Q34638205-2353CD62-7D75-4E5D-B031-C7164D86017D Q34694448-9F3EAA2C-7B2C-4241-A44D-94F844E405BD Q34730407-D46FDD95-EA09-4510-98FE-5FD47595CBF6 Q34793193-602EB83B-FC90-4A94-8F98-BFE5249FAE50 Q34898069-91367E67-FCCA-4E57-A103-D9F5B997DB26 Q34942750-A07CD9E0-CA15-4D17-A0E6-72781D1066E7 Q34987470-F214827D-0A9B-459D-A080-4C507BA3FAED

P2860

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q37496608

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epidemiological evidence for c ...... active antiretroviral therapy.

@en

Epidemiological evidence for c ...... active antiretroviral therapy.

@nl

type

label

Epidemiological evidence for c ...... active antiretroviral therapy.

@en

Epidemiological evidence for c ...... active antiretroviral therapy.

@nl

prefLabel

Epidemiological evidence for c ...... active antiretroviral therapy.

@en

Epidemiological evidence for c ...... active antiretroviral therapy.

@nl

P1433

Q37496608-430947E8-0C31-4F85-9291-CC56D67B9ABC

P1476

Q37496608-13F1B892-A197-4956-805E-6E955CA8D397

P2093

Q37496608-22EEAACD-731A-4F25-9F82-AB5CC4EFAD8F

Q37496608-2556AB4F-90E5-45EA-B3B8-E2A6976AE0AD

Q37496608-2B283FA0-D48D-4DBB-83EF-6979B07E1B1C

Q37496608-79A42E11-8802-4F2A-AFF4-017FD1BB0430

Q37496608-A839B8CC-5F94-48BB-A39A-C04706BA8E01

Q37496608-CB0D465B-CF4C-4CAF-8B0B-D65312D7B070

Q37496608-F2AFF840-696E-4F87-B7C3-6BEE62C3CAE2

P2860

Q37496608-01A7EB74-01EB-4F33-85F0-CCBF2F4D0C27

Q37496608-03291354-1DA1-4A9A-93A2-B41A95DF3AC0

Q37496608-0F44B019-206E-4FCD-9704-B0DFC38CB648

Q37496608-1D5D7E6C-9FD8-4B84-8025-5101F5600630

Q37496608-2597B05F-DD5B-41F4-8DF6-62718752B3E5

Q37496608-2C93EDB2-95C7-4E2F-98E4-9F202EF4DCF0

Q37496608-316C4C09-A3D5-4EA2-8E93-08413CFA607F

Q37496608-37A117D3-9DEA-4684-BEB9-2E60098552E5

Q37496608-3F0FF012-66D9-48C2-BFAE-A9010682E600

Q37496608-46B6F870-6C23-45D9-8621-4EE53A77243A

P304

Q37496608-2E2DA400-0784-4115-89E6-3FE227C2F10B

P31

Q37496608-BC57ABCE-4577-461E-8FFE-667B8E97B573

P356

Q37496608-9330062D-B393-4AD4-BB35-E47C66A1E463

P407

Q37496608-A05ADBAE-D90E-46F1-87A9-D9475ACE8D18

P433

Q37496608-06A2990D-FDDF-4BFB-8276-563F7D51136B

P478

Q37496608-9A04D95B-08D3-4EAC-9CB9-6C2393DFC3D0

P50

Q37496608-01C13725-D391-4003-B974-892D849CDFB9

Q37496608-75AE94FE-A911-449C-9ECF-51D7D573B8D1

P577

Q37496608-557BFD1D-290F-47C5-8981-41327B61732F

P698

Q37496608-AFD1643E-49AC-4C20-8A3F-7DA9036DC502

P921

Q37496608-40826F61-86AA-4C60-9F39-16FB024E14A6

Q37496608-9DAA21D8-78CA-4C4B-B6E8-4503E2E50C73

Q37496608-A9A99A79-1DF5-498D-9A80-FFCE8AC589C3

Q37496608-ECD79736-35C7-441A-97CA-CE92A6D30B7D

Q37496608-ED32A3F5-6E20-4A86-BF74-8777C9D9E637

P932

Q37496608-78F31F05-B177-447B-96BD-88BA81B2521A

P356

CIRCULATIONAHA.107.189624

P1433

P1476

Epidemiological evidence for c ...... active antiretroviral therapy.

@en

P2093

Andrew Carr

http://www.w3.org/2001/XMLSchema#string

Daniel Klein

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Schouten

http://www.w3.org/2001/XMLSchema#string

Judith S Currier

http://www.w3.org/2001/XMLSchema#string

Marek Smieja

http://www.w3.org/2001/XMLSchema#string

Paul E Sax

http://www.w3.org/2001/XMLSchema#string

Working Group 2

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

CD4+ count-guided interruption of antiretroviral treatment

A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study.

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era.

Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.

P304

e29-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.107.189624

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18566319

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

antiretroviral drug

P932

5153327

http://www.w3.org/2001/XMLSchema#string